Shanghai Yizhong Pharmaceutical Co. Ltd. Class ASSE: 688091

"Shanghai Yizhong Pharmaceutical Co., Ltd."Voluntary Disclosure Announcement on Receipt of a Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-001

Aug 18, 2026 · Issued by Shanghai Yizhong Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Voluntary Disclosure Announcement on Receipt of a Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-001

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Shanghai Yizhong Pharmaceutical Co. Ltd. Class A

"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on the Company and Its Wholly-owned Subsidiaries Using Certain Idle Raised Funds for Cash ManagementAug 7
"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing SharesAug 4
"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Shareholding Increase by the Actual ControllerJul 31
"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Cumulative Repurchase of 1% Shares through Call Auction and Progress of Share RepurchaseJul 29

All Shanghai Yizhong Pharmaceutical Co. Ltd. Class A news releases